CLDX
Price
$20.82
Change
+$0.11 (+0.53%)
Updated
May 2, 02:38 PM (EDT)
Capitalization
1.37B
97 days until earnings call
NTLA
Price
$9.18
Change
+$0.54 (+6.25%)
Updated
May 2, 02:57 PM (EDT)
Capitalization
894.39M
6 days until earnings call
Ad is loading...

CLDX vs NTLA

Header iconCLDX vs NTLA Comparison
Open Charts CLDX vs NTLABanner chart's image
Celldex Therapeutics
Price$20.82
Change+$0.11 (+0.53%)
Volume$100
Capitalization1.37B
Intellia Therapeutics
Price$9.18
Change+$0.54 (+6.25%)
Volume$1K
Capitalization894.39M
CLDX vs NTLA Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. NTLA commentary
May 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a StrongBuy and NTLA is a Buy.

Ad is loading...
COMPARISON
Comparison
May 02, 2025
Stock price -- (CLDX: $20.71 vs. NTLA: $8.64)
Brand notoriety: CLDX and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 77% vs. NTLA: 62%
Market capitalization -- CLDX: $1.37B vs. NTLA: $894.39M
CLDX [@Biotechnology] is valued at $1.37B. NTLA’s [@Biotechnology] market capitalization is $894.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 6 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than NTLA.

Price Growth

CLDX (@Biotechnology) experienced а +5.77% price change this week, while NTLA (@Biotechnology) price change was +5.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +8.32%, and the average quarterly price growth was -5.52%.

Reported Earning Dates

CLDX is expected to report earnings on Aug 07, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.38B) has a higher market cap than NTLA($894M). CLDX YTD gains are higher at: -18.045 vs. NTLA (-25.901). CLDX has higher annual earnings (EBITDA): -191.9M vs. NTLA (-523.98M). CLDX has more cash in the bank: 725M vs. NTLA (602M). CLDX has less debt than NTLA: CLDX (3.81M) vs NTLA (210M). NTLA has higher revenues than CLDX: NTLA (57.9M) vs CLDX (7.02M).
CLDXNTLACLDX / NTLA
Capitalization1.38B894M154%
EBITDA-191.9M-523.98M37%
Gain YTD-18.045-25.90170%
P/E RatioN/AN/A-
Revenue7.02M57.9M12%
Total Cash725M602M120%
Total Debt3.81M210M2%
FUNDAMENTALS RATINGS
CLDX vs NTLA: Fundamental Ratings
CLDX
NTLA
OUTLOOK RATING
1..100
107
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
9392
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for CLDX (59). This means that NTLA’s stock grew somewhat faster than CLDX’s over the last 12 months.

CLDX's Profit vs Risk Rating (62) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that CLDX’s stock grew somewhat faster than NTLA’s over the last 12 months.

NTLA's SMR Rating (92) in the Biotechnology industry is in the same range as CLDX (93). This means that NTLA’s stock grew similarly to CLDX’s over the last 12 months.

CLDX's Price Growth Rating (60) in the Biotechnology industry is in the same range as NTLA (61). This means that CLDX’s stock grew similarly to NTLA’s over the last 12 months.

CLDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that CLDX’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXNTLA
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 17 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGVRX38.40N/A
N/A
JPMorgan Growth Advantage R5
MURRX22.84N/A
N/A
MFS Utilities R2
PASIX10.64N/A
N/A
PACE Alternative Strategies A
JUSQX15.57N/A
N/A
JPMorgan US Small Company R4
HOMPX13.56N/A
N/A
HW Opportunities MP

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-0.58%
BEAM - CLDX
51%
Loosely correlated
-0.50%
DNLI - CLDX
51%
Loosely correlated
-3.54%
KYMR - CLDX
49%
Loosely correlated
+0.82%
NTLA - CLDX
48%
Loosely correlated
-2.59%
RVMD - CLDX
47%
Loosely correlated
+0.64%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-2.59%
VCYT - NTLA
69%
Closely correlated
-2.59%
CRSP - NTLA
66%
Loosely correlated
-2.43%
BEAM - NTLA
64%
Loosely correlated
-0.50%
RXRX - NTLA
60%
Loosely correlated
-1.61%
RCKT - NTLA
59%
Loosely correlated
+3.01%
More